Jerini To Submit Complete Response Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
With five companies in a race to control the HAE therapeutic space, three announce progress.
You may also be interested in...
Latest Dyax Deal For DX-88 Should Bring In $10 Million
Massachusetts biotech licenses lead compound to Italy’s Dompe Farmaceutici for angioedema conditions.
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
Latest Dyax Deal For DX-88 Should Bring In $10 Million
Massachusetts biotech licenses lead compound to Italy’s Dompe Farmaceutici for angioedema conditions.